← Leaderboards
Farrokh Dehdashti
Washington University
$4,034,096
Attributed
$7,952,793
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,952,793 · 6
By mechanism
R01$7,168,513 · 4
R21$784,280 · 2
Top collaborators
- Kian H Lim6 shared
- Yongjian Liu6 shared
- Cynthia X Ma4 shared
- Kooresh Isaac Shoghi4 shared
Most similar at Washington University
Same institution · by research overlap
- Timothy J Eberlein$71,591,509
- John F Dipersio$33,235,840
- John Morris$91,785,862
- Randall J Bateman$192,965,895
- Eric J Lenze$35,080,787
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPositron-Emission TomographyRadiotracerResponseChemotherapyBiopsyMorbidity - Disease RateDisease ProgressionImagePredicting ResponseResistanceBaseImmunohistochemistryIn VivoTargeted TreatmentUptakeNeoplasm MetastasisDetectionPreclinical StudyTreatment ResponseClinical TrialsPatient SelectionImaging AgentFuture
Grant awards (18)
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$1,254,028
R01 · FY2025 · CA
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$595,711
R01 · FY2024 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$252,589
R01 · FY2024 · CA · contact PI
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$614,261
R01 · FY2023 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$168,482
R01 · FY2023 · CA · contact PI
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer$647,179
R01 · FY2022 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$591,868
R01 · FY2022 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$597,298
R01 · FY2021 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$580,914
R01 · FY2020 · CA · contact PI
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy$575,716
R01 · FY2019 · CA · contact PI
ASSESSMENT OF FUNCTIONAL STATUS OF ESTROGEN RECEPTORS IN BREAST CANCER BY PET$142,588
R01 · FY2017 · CA · contact PI
ASSESSMENT OF FUNCTIONAL STATUS OF ESTROGEN RECEPTORS IN BREAST CANCER BY PET$279,075
R01 · FY2016 · CA · contact PI
A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB$315,400
R21 · FY2015 · CA · contact PI
ASSESSMENT OF FUNCTIONAL STATUS OF ESTROGEN RECEPTORS IN BREAST CANCER BY PET$279,075
R01 · FY2015 · CA · contact PI
A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB$315,400
R21 · FY2014 · CA · contact PI
Positron Emission Tomography in Prostate Cancer$299,223
R01 · FY2008 · CA · contact PI
Positron Emission Tomography in Prostate Cancer$290,506
R01 · FY2007 · CA · contact PI
CLINICAL ASSESSMENT OF TUMOR HYPOXIA WITH PET$153,480
R21 · FY2000 · CA